Bispecific Antibody Active in Relapsed/Refractory Small Cell Lung Cancer

(MedPage Today) -- A first-in-class bispecific antibody achieved durable responses in a fourth of patients with advanced small cell lung cancer (SCLC) and disease control in more than half, a preliminary clinical trial showed. Tarlatamab, targeting...
Source: MedPage Today Hematology/Oncology - Category: Hematology Source Type: news